Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 6/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30929415 | 0.94 | F2 (0.44) | F2F7F3PREPBRD4 | |
| SCHEMBL30929417 | 0.90 | F2 (0.41) | F2F7F3PREPBRD4 | |
| SCHEMBL30929478 | 0.90 | F2 (0.41) | F2F7F3PREPTP53 | |
| SCHEMBL30929456 | 0.89 | F2 (0.41) | F2F7F3PREPBRD4 | |
| SCHEMBL30929459 | 0.89 | F2 (0.41) | F2F7F3PREPBRD4 | |
| SCHEMBL30929453 | 0.89 | F2 (0.40) | F2F7F3PREPENPP2 | |
| SCHEMBL30929452 | 0.88 | F2 (0.45) | F2F7F3PREPBRD4 | |
| SCHEMBL30929434 | 0.87 | BRD4 (0.46) | F2F7F3PREPBRD4 | |
| SCHEMBL30929461 | 0.82 | F2 (0.41) | F2F7F3PREPP2RX3 | |
| SCHEMBL30929399 | 0.81 | F2 (0.47) | F2F7F3PREPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626891-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | Omeros Corporation (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024118840-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | OMEROS CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | F2 107/4885F7 1393/4885F3 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.